<DOC>
	<DOCNO>NCT01986348</DOCNO>
	<brief_summary>This open-label , multicenter , Phase 2 study evaluate efficacy safety oral Selinexor patient recurrent glioma .</brief_summary>
	<brief_title>A Phase 2 Study Evaluating Efficacy Safety Selinexor ( KPT-330 ) Patients With Recurrent Gliomas</brief_title>
	<detailed_description>This open-label , multicenter , Phase 2 study evaluate efficacy safety oral selinexor patient recurrent glioma . Initially , study include 2 arm : exploratory Surgical Arm ( Arm A ) sequential enrollment patient require surgery medical arm ( Arm B ) patient eligible surgery . Enrollment Arm B stop explore alternative dose Protocol Versions â‰¥ 4.0 potentially improve tolerability . Four arm ( Arms C , D , E , F ) add Medical Arm Protocol Version 4.0 . Patients primary population enrol Protocol Version 4.0 randomize Arm C Arm D ( approximately 30 patient per arm ) explore alternative dose potentially improve tolerability . Patients malignant gliomas glioblastoma ( GBM ) ( Arm E ; approximately 20 patient ) patient GBM AG refractory antiangiogenic treatment ( Arm F ; approximately 10 patient ) enrol evaluate preliminary evidence efficacy Selinexor exploratory population . After screen registration/randomization study , patient enrol Arms A E randomize Arm C receive 60 mg Selinexor orally twice weekly . Patients randomized Arm D receive 80 mg Selinexor orally weekly . Enrollment Arm F begin first stage result Arms C D available . Dosing Arm F select base first stage result Arms C D. Patients treat progression disease development unacceptable toxicity . All patient undergo End Treatment ( EOT ) visit .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>Confirmed diagnosis , follow : 1 . Arms A , B , C , D : Pathologically confirm GBM ( include histologic variant ) first diagnosis radiographic evidence recurrent disease treatment radiotherapy temozolomide ; 2 . Arm E : Pathologically confirm malignant glioma GBM ( WHO Grade 2 Grade 3 ) , radiographic evidence recurrent disease treatment radiotherapy least one line systemic treatment ; 3 . Arm F : Pathologically confirm GBM ( include histologic variant ) AG refractory antiangiogenic treatment ( define recurrence progression disease per RANO criterion prior therapy bevacizumab direct VEGF/VEGFR inhibitor ) radiographic evidence recurrent disease treatment radiotherapy temozolomide ; 18 year age old Patients enrol medical arm ( Arms B , C , D , E , F ) must stable decrease dose corticosteroid ( none ) least 5 day prior baseline MRI ; Measurable disease ( accord RANO guideline ) Surgical arm ( Arm A ) must predict preoperatively sufficiently size tumor resect provide tissue sample exploratory assessment . Markedly decrease visual acuity attribute cause GBM Arms A , C , D , malignant glioma GBM ( WHO Grade 2 Grade 3 ) Arm E , GBM AG refractory antiangiogenic treatment Arm F. Known active hepatitis A , B , C Patients coagulation problem medically significant bleed month prior start treatment ( e.g. , peptic ulcer , epistaxis , spontaneous bleeding ) . Prior history DVT PE exclusionary . Patients must significantly diseased obstruct gastrointestinal tract , malabsorption , uncontrolled vomit diarrhea , inability swallow oral medication . Arms A , B , C , D , : Prior treatment bevacizumab direct VEGF/ VEGFR inhibitor . For question definition direct VEGF/VEGFR inhibitor , consult Sponsor . Arms C D : body surface area &lt; 1.2 m2 . &lt; 24 day prior temozolomide , &lt; 6 week nitrosourea , &lt; 4 week chemotherapy investigational agent prior start treatment within study . For Arm F : &lt; 6 week prior bevacizumab direct VEGF/VEGFR inhibitor prior start treatment within study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GBM</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>selinexor</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>brain tumor</keyword>
	<keyword>brain cancer</keyword>
	<keyword>Glioma</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Oligodendrogliomas</keyword>
	<keyword>Oligo-astrocytomas</keyword>
</DOC>